Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Trial Evaluating the Safety, Tolerability, PK, and Efficacy of QTX3034 in Patients With Solid Tumors With KRASG12D Mutation

NCT06227377 is registered in ClinicalTrials.gov with Quanta Therapeutics as lead sponsor.

NCT NCT06227377
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06227377 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Trial Evaluating the Safety, Tolerability, PK, and Efficacy of QTX3034 in Patients With Solid Tumors With KRASG12D Mutation
Lead sponsor
Quanta Therapeutics
Phase
Phase 1
Overall status
Recruiting
Start date
February 5, 2024
Completion date
April 1, 2027
Enrollment
250 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors